Prevalence of Factor V Leiden in Accelerated Forms of Coronary Artery Disease

James C Fang; Joseph P Miletich; Paul M Ridker

doi:10.1055/s-0038-1657706

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(03): 1161-1162
DOI: 10.1055/s-0038-1657706

Letter to the Editor

Schattauer GmbH Stuttgart

Prevalence of Factor V Leiden in Accelerated Forms of Coronary Artery Disease

Authors

James C Fang

The Cardiovascular Division (JCF, PMR), Department of Medicine, Brigham and Women’s Hospital, Boston, MA and the Division of Laboratory Medicine (JPM), Washington University School of Medicine, St. Louis, MO, USA
Joseph P Miletich

The Cardiovascular Division (JCF, PMR), Department of Medicine, Brigham and Women’s Hospital, Boston, MA and the Division of Laboratory Medicine (JPM), Washington University School of Medicine, St. Louis, MO, USA
Paul M Ridker

The Cardiovascular Division (JCF, PMR), Department of Medicine, Brigham and Women’s Hospital, Boston, MA and the Division of Laboratory Medicine (JPM), Washington University School of Medicine, St. Louis, MO, USA

Abstract

PDF Download

PDF (392 kb)

References

References
1 Dahlbäck B. New Molecular Insights into the Genetics of Thrombophilia: Resistance to Activated Protein C Caused by Arg506 to Gin Mutation in Fac tor V as a Pathogenic Risk Factor for Venous Thrombosis. Thromb Haemost 1995; 74 (01) 139-148
2 Svensson PJ, Dahlbäck B. Resistance of Activated Protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
3 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men. N Engl J Med 1995; 332: 912-917
4 Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to Activated Protein C and Risk of Premature Myocardial Infarction. Lancet 1994; 344: 1709-1710
5 Holm J, Zӧller B, Svensson PJ, Bemtorp E, Erhardt L, Dahlbäck B. Myocar dial Infarction Associated with Homozygous Resistance to Activated Protein C. Lancet 1994; 344: 952-953
6 Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in Coagulation Factor V Associated with Resistance to Activated Protein C in Patients with Coronary Artery Disease. Lancet 1995; 345: 526-527
7 Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular Tissue Plasminogen Activator and the Development of Coronary Artery Disease in Heart-Trans- plant Recipients. N Engl J Med 1995; 333: 1111-1116
8 Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic Distribution of Factor V Leiden Among 4047 Men and Women: Implications for Screening and Prevention of Venous Thromboembolism. JAMA 1997; 277: 1305-1307